Figure 5
From: COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
Longitudinal analysis of ACE2 binding inhibition and anti-RBD IgG levels in COVID-19 patients. Mean ACE2 binding inhibition (%) and IgG responses (MFI) for wild-type RBD against time post positive PCR test for samples (n = 149) taken from 1 to 92 days post PCR are shown (a,b). Black dots indicate mean responses with standard deviation indicated by the error bars. The same analysis is then shown for longitudinal samples of selected donors (n = 6) for wild-type (c,d) and RBD delta (e,f). For all RBD mutants, mean ACE2 binding inhibition (%) and mean IgG responses (MFI) 1 to 92 days post PCR are shown (g,h). Each variant is illustrated by a different color according to the figure key.
